Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C13H21N3.ClH |
Molecular Weight | 255.787 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@]12CCCN(CCC)[C@]1([H])CC3=C(C2)NN=C3
InChI
InChIKey=HJHVRVJTYPKTHX-HTMVYDOJSA-N
InChI=1S/C13H21N3.ClH/c1-2-5-16-6-3-4-10-7-12-11(8-13(10)16)9-14-15-12;/h9-10,13H,2-8H2,1H3,(H,14,15);1H/t10-,13-;/m1./s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/8099277Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9806217 | https://www.ncbi.nlm.nih.gov/pubmed/2566488 | https://www.ncbi.nlm.nih.gov/pubmed/9926830 | https://www.ncbi.nlm.nih.gov/pubmed/28434589
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8099277
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9806217 | https://www.ncbi.nlm.nih.gov/pubmed/2566488 | https://www.ncbi.nlm.nih.gov/pubmed/9926830 | https://www.ncbi.nlm.nih.gov/pubmed/28434589
Quinpirole (LY 171,555) is a psychoactive drug and research chemical which acts as a selective D2 and D3 receptor agonist. Quinpirole is the most widely used D2 agonist in in vivo and in vitro studies. Specific quinpirole binding in rat brain was saturable, and dependent on temperature, membrane concentration, sodium concentration and guanine nucleotides. Saturation analysis revealed high affinity binding characteristics (KD = 2.3 nM) which were confirmed by association-dissociation kinetics. The regional distribution of [3H]quinpirole binding sites roughly paralleled the distribution of [3H]spiperone binding sites, with greatest densities present in the striatum, nucleus accumbens and olfactory tubercles. A variety of drugs, most notably monoamine oxidase inhibitors (MAOls), inhibit the binding of [3H]quinpirole, but not [3H]spiperone or [3H](-)N-n-Propylnorapomorphine, in rat striatal membranes by a mechanism that does not appear to involve the enzymatic activity of MAO. Clinically antidepressant MAOIs exhibited selectivity between sites labeled by [3H]quinpirole and [3H]spiperone as did a number of structurally related propargylamines and N-acylethylenediamine derivatives and other drugs such as debrisoquin and phenylbiguanide. Quinpirole has been shown to increase locomotion and sniffing behavior in mice and induces compulsive behavior symptomatic of obsessive compulsive disorder in rats.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL234 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24831693 |
9.8 nM [EC50] | ||
Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24831693 |
19.0 nM [EC50] | ||
Target ID: CHEMBL2056 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17154515 |
|||
Target ID: CHEMBL219 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12617906 |
9.9 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Systemic hemodynamic and regional blood flow effects of LY141865, a selective dopamine receptor agonist. | 1984 Sep |
|
A comparison of the effects of cholinergic and dopaminergic agents on scopolamine-induced hyperactivity in mice. | 1990 Nov |
|
Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. | 1990 Sep 13 |
|
Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. | 1992 Apr 10 |
|
Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. | 1995 Nov |
|
Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations. | 1998 May 1 |
|
Acute nicotine pretreatment augments dopaminergic pulmonary vasodilation. | 1998 Oct |
|
Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors. | 1999 Jun |
|
Catecholamines participate in the induction of ornithine decarboxylase gene expression in normal and hyperplastic mouse kidney. | 1999 May 31 |
|
Quinpirole, 8-OH-DPAT and ketanserin modulate catalepsy induced by high doses of atypical antipsychotics. | 1999 Nov |
|
Dopamine D1- and D2-like receptor mechanisms in relapse to cocaine-seeking behavior: effects of selective antagonists and agonists. | 2000 Aug |
|
Enhanced vulnerability to cocaine self-administration is associated with elevated impulse activity of midbrain dopamine neurons. | 2000 Dec 1 |
|
D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade. | 2000 Dec 15 |
|
Effects of dopaminergic agents on carrageenan hyperalgesia after intrathecal administration to rats. | 2001 Apr 20 |
|
Effect of olanzapine on functional responses from sensitized D1-dopamine receptors in rats with neonatal dopamine loss. | 2001 Aug |
|
Differential effects of D1- and D2-like compounds on cocaine self-administration in Lewis and Fischer 344 inbred rats. | 2001 Nov |
|
Blockade of spinal dopamine D2 receptors enhances the pressor effect of intravenous quinpirole in normotensive, conscious rats. | 2002 Feb |
|
Cocaine and amphetamine depress striatal GABAergic synaptic transmission through D2 dopamine receptors. | 2002 Feb |
|
Relapse to cocaine- and heroin-seeking behavior mediated by dopamine D2 receptors is time-dependent and associated with behavioral sensitization. | 2002 Jan |
|
Concurrent activation of dopamine D1 and D2 receptors is required to evoke neural and behavioral phenotypes of cocaine sensitization. | 2002 Jul 15 |
|
Effect of repeated treatment with mirtazapine on the central dopaminergic D2/D3 receptors. | 2002 Jul-Aug |
|
Direct and indirect actions of dopamine on the membrane potential in medium spiny neurons of the mouse neostriatum. | 2002 Mar |
|
DARPP-32 mediates serotonergic neurotransmission in the forebrain. | 2002 Mar 5 |
|
A potential antidepressant activity of SA4503, a selective sigma 1 receptor agonist. | 2002 Nov |
|
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. | 2002 Nov |
|
Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models. | 2002 Oct |
|
Impaired D2 dopamine receptor function in mice lacking type 5 adenylyl cyclase. | 2002 Sep 15 |
|
Effect of amphetamine repeated treatment on the feeding behavior in neuropeptide Y-overexpressing mice. | 2002 Sep 6 |
|
Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems. | 2003 Dec |
|
Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice. | 2003 May |
|
Selective modifications in GAD67 mRNA levels in striatonigral and striatopallidal pathways correlate to dopamine agonist priming in 6-hydroxydopamine-lesioned rats. | 2003 Nov |
|
Haloperidol, but not clozapine, produces dramatic catalepsy in delta9-THC-treated rats: possible clinical implications. | 2003 Oct |
|
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. | 2004 Aug |
|
Morphine state-dependent learning: sensitization and interactions with dopamine receptors. | 2004 Aug 23 |
|
Dopamine receptor activation in bovine pinealocyte via a cAMP-dependent transcription pathway. | 2005 Apr |
|
D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways. | 2005 Feb 23 |
|
Dyskinesias occur in response to saline and naltrexone alone after priming with combination of dopaminergic agents and naltrexone in the MPTP parkinsonian monkeys. | 2005 Jun-Jul |
|
Locomotor activity and cocaine-seeking behavior during acquisition and reinstatement of operant self-administration behavior in rats. | 2005 May 28 |
|
The influence of central administration of dopaminergic and cholinergic agents on morphine-induced amnesia in morphine-sensitized mice. | 2006 Jan |
|
Control of the subthalamic innervation of substantia nigra pars reticulata by D1 and D2 dopamine receptors. | 2006 Mar |
|
Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors. | 2009 Jul |
|
Effect of repeated co-treatment with fluoxetine and amantadine on the behavioral reactivity of the central dopamine and serotonin system in rats. | 2009 Sep-Oct |
|
Amphetamine up-regulates activator of G-protein signaling 1 mRNA and protein levels in rat frontal cortex: the role of dopamine and glucocorticoid receptors. | 2010 Jun 16 |
|
Pharmacological, neurochemical, and behavioral profile of JB-788, a new 5-HT1A agonist. | 2010 Sep 1 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28434589
0.5 mg/kg (two injections/week)
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9806217
Adult, male, Sprague-Dawley rats (200-250g; Harlan Labs, Indianapolis, IN) were sacrificed by decapitation, the brains rapidly removed and dissected on ice. Striatal tissue was homogenized in 30 vol. ice-cold 0.32 M sucrose using a glass homogenizer and Teflon pestle. The crude nuclear fraction (P1), the pellet formed from centrifugation of the pellet at 1,000 x g for 10 mitt; the crude synaptosomal fraction (P2), the pellet formed by the centrifugation of the resulting supernatant at 20,000 x g for 30 min; Subfractionation of the crude synaptosomal fraction (P2) was performed by centrifugation of freshly prepared P2 fraction suspended in 0.32 M sucrose over a discontinuous gradient of 0.8 M and 1.2 M sucrose at 110,000 x g for 70 min. Three subfractions were collected. The myelin fraction (P2A) was collected at the 0.32 M/O.8 M sucrose interface; the synaptosomal fraction (P2B) at the 0.8 /1.2 M sucrose interface; and the mitochondrial fraction (P2C), the final pellet. All resulting fractions were resuspended in assay buffer and centrifuged at 100,000 x g for 30 min. The resulting pellets were used for receptor binding assays. The final fraction pellets were resuspended in assay buffer (50 mM Tris-HCl, 5 mM KCI, 2 mM MgCl2, and 2 mM CaCl2, pH 7.4 at 23°C) to yield a final protein concentration of 400 mkg/tube. Binding assays were performed in duplicate in disposable polystyrene tubes. Saturation analyses were performed in the major subcellular fractions to determine radioligand affinity. For saturation analyses, eight concentrations of [3H]quinpirole (43 Ci/mmol; NEN DuPont Research Products, Boston, MA) were used (0.1 to 30 nM). Because [3H]quinpirole exhibited similar affinity in the major subcellular fractions, single point analyses were used for subsequent experiments. For single point studies, the final concentration of [3H]quinpirole was ~2 nM Binding was initiated by the addition of resuspended subcellular fractionate. The total assay volume was 0.5 ml. Tubes were incubated at 23°C for 4 h
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66884
Created by
admin on Fri Dec 15 15:23:57 GMT 2023 , Edited by admin on Fri Dec 15 15:23:57 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL240773
Created by
admin on Fri Dec 15 15:23:57 GMT 2023 , Edited by admin on Fri Dec 15 15:23:57 GMT 2023
|
PRIMARY | |||
|
C152129
Created by
admin on Fri Dec 15 15:23:57 GMT 2023 , Edited by admin on Fri Dec 15 15:23:57 GMT 2023
|
PRIMARY | |||
|
85798-08-9
Created by
admin on Fri Dec 15 15:23:57 GMT 2023 , Edited by admin on Fri Dec 15 15:23:57 GMT 2023
|
PRIMARY | |||
|
T6I2W5V2K1
Created by
admin on Fri Dec 15 15:23:57 GMT 2023 , Edited by admin on Fri Dec 15 15:23:57 GMT 2023
|
PRIMARY | |||
|
DTXSID8045519
Created by
admin on Fri Dec 15 15:23:57 GMT 2023 , Edited by admin on Fri Dec 15 15:23:57 GMT 2023
|
PRIMARY | |||
|
55397
Created by
admin on Fri Dec 15 15:23:57 GMT 2023 , Edited by admin on Fri Dec 15 15:23:57 GMT 2023
|
PRIMARY | |||
|
U-9
Created by
admin on Fri Dec 15 15:23:57 GMT 2023 , Edited by admin on Fri Dec 15 15:23:57 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD